Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP, Human Resources | May 03, 2016 | May 06, 2016 |
| MANNKIND CORPMNKD · Entity 4792 | Chief People & Workpl Officer | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 03, 2016 · Filed May 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,671 |
Reported balance
After 2016-05-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-05-03 · Grant · Acquired 2,046 · Balance 25,671 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2: These shares include the following RSUs granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019; and 2,046 RSUs which vest in two equal installments of 675 on 5/3/2018 and 5/3/2019 and one installment of 696 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.35 · Expires 2026-05-03 | Direct | 17,422 |
Reported balance
After 2016-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-05-03 · Grant · Acquired 17,422 · Balance 17,422 F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 593.142 |
Reported balance
Holding disclosure · report date 2016-05-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 593.142 F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
F2: These shares include the following RSUs granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019; and 2,046 RSUs which vest in two equal installments of 675 on 5/3/2018 and 5/3/2019 and one installment of 696 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,123,950 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Exercise / conversion · Acquired 93,790 · Balance 1,123,950 F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F2: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,090,298 |
Reported balance
After 2026-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-15 · Tax withholding · Disposed 33,652 · Balance 1,090,298 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,082,045 |
Reported balance
After 2026-07-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-15 · Tax withholding · Disposed 8,253 · Balance 1,082,045 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,070,473 |
Reported balance
After 2026-07-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-07-15 · Tax withholding · Disposed 11,572 · Balance 1,070,473 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,058,142 |
Reported balance
After 2026-07-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-07-15 · Tax withholding · Disposed 12,331 · Balance 1,058,142 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Exercise / conversion · Disposed 93,790 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
F2: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2022 Filed May 21, 2022 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 5,941 | $3.19 | $18,951.79 |
DisclosureSEC source: 0001209191-22-031201 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,069 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028675 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,010 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028675 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,010 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock,$.01 par value | 9,225 | $2.71 | $24,999.75 |
DisclosureSEC source: 0001209191-22-014095 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,010 Read SEC document |
| February 28, 2022 Filed Aug 25, 2022 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock,$.01 par value | 9,225 | $2.71 | $24,999.75 |
DisclosureSEC source: 0001209191-22-047426 · doc4a.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,010 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 22:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 4,254 | $3.17 | $13,485.18 |
DisclosureSEC source: 0001209191-22-006417 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,785 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 10, 2022 02:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 2,254 | $3.17 | $7,145.18 |
DisclosureSEC source: 0001209191-22-008266 · doc4a.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,785 F1 · shares: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on January 31, 2022. The amended number of shares purchased were limited by Section 423(b)(8) of the Code. Read SEC document |
| January 31, 2022 Filed Aug 25, 2022 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 2,254 | $3.17 | $7,145.18 |
DisclosureSEC source: 0001209191-22-047424 · doc4a.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,785 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| August 27, 2021 Filed Aug 28, 2021 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 14,177 | $4.91 | $69,609.07 |
DisclosureSEC source: 0001209191-21-053767 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,531 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 4,476 | $2.99 | $13,383.24 |
DisclosureSEC source: 0001209191-21-049139 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,708 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2021. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034456 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,708 F3 · shares: The restricted stock unit will vest on May 17, 2024 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 17, 2021. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 18, 2021 until May 17, 2024 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 68,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034456 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,708 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 23:18 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $1.33 | $6,650.00 |
DisclosureSEC source: 0001209191-21-006890 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,991 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2021 representing the maximum allowable under the Plan for this period. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 23:10 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 1,729 | $3.33 | $5,757.57 |
DisclosureSEC source: 0001209191-20-065575 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,991 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:06 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048846 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,720 F3 · shares: The restricted stock unit will vest on May 22, 2023 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on August 27, 2020. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from August 27, 2020 until May 22, 2023 related to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:06 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 164,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048846 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,720 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 22:41 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $1.25 | $6,250.00 |
DisclosureSEC source: 0001209191-20-044833 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,720 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on July 31, 2020 representing the maximum allowable under the Plan for this period. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $2.70 Strike: $2.70 | $54,000.00 |
DisclosureSEC source: 0001209191-20-013626 · doc4.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Stock Options · 20,000 shares Expires 2027-02-16 F2 · kind: On February 16, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 25, 2020, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 28,144 | $1.42 Strike: $1.42 | $39,964.48 |
DisclosureSEC source: 0001209191-20-013626 · doc4.xml · derivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,144 Underlying: Stock Options · 28,144 shares Expires 2027-05-25 F1 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 25, 2020, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 22:57 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 15,021 | $1.51 | $22,681.71 |
DisclosureSEC source: 0001209191-20-011695 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,720 F1 · shares: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 02:17 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $0.95 | $4,750.00 |
DisclosureSEC source: 0001209191-20-006175 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,741 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on January 31, 2020 representing the maximum allowable under the Plan for this period. Read SEC document |
| December 27, 2019 Filed Dec 28, 2019 01:25 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 2,044 | $1.31 | $2,677.64 |
DisclosureSEC source: 0001209191-19-062049 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,996 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 31, 2019 Filed Aug 1, 2019 00:47 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $0.95 | $4,750.00 |
DisclosureSEC source: 0001209191-19-043928 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,785 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on July 31, 2019 representing the maximum allowable under the Plan for this period. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:20 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 234,000 | $1.32 Strike: $1.32 | $308,880.00 |
DisclosureSEC source: 0001209191-19-030363 · doc4.xml · derivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,000 Underlying: Stock Options · 234,000 shares Expires 2029-05-14 F1 · kind: Annual Equity Award: 25% vesting on the anniversary of the vesting determination date and 1/48th per month thereafter; being fully vested on the fourth anniversary of the vesting determination date. Read SEC document |
| February 20, 2019 Filed Feb 25, 2019 11:09 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 36,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012817 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,785 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Restricted stock units shall vest and be delivered on February 20, 2020. Read SEC document |
| January 31, 2019 Filed Jan 31, 2019 23:15 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $1.07 | $5,350.00 |
DisclosureSEC source: 0001209191-19-006273 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,040 F2 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on January 31, 2019 representing the maximum allowable under the Plan for this period. Read SEC document |
| December 23, 2018 Filed Jan 31, 2019 23:15 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 2,044 | $1.09 | $2,227.96 |
DisclosureSEC source: 0001209191-19-006273 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,040 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 23:09 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 14,124 | $1.77 | $24,999.48 |
DisclosureSEC source: 0001209191-18-058795 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,084 Read SEC document |
| November 14, 2018 Filed Mar 13, 2019 16:21 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 14,124 | $1.77 | $24,999.48 |
DisclosureSEC source: 0001209191-19-019067 · doc4a.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · EVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,084 Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 23:21 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $2.70 Strike: $2.70 | $54,000.00 |
DisclosureSEC source: 0001209191-18-045606 · doc4.xml · derivative · entry 3 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Stock Options · 20,000 shares Expires 2027-02-16 F3 · kind: On February 16, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On August 2, 2018, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 23:21 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 28,144 | $1.42 Strike: $1.42 | $39,964.48 |
DisclosureSEC source: 0001209191-18-045606 · doc4.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,144 Underlying: Stock Options · 28,144 shares Expires 2027-05-25 F2 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On August 2, 2018, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 23:21 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $1.31 | $6,550.00 |
DisclosureSEC source: 0001209191-18-045606 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,960 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on August 2, 2018, representing the maximum allowable under the Plan for this period. Read SEC document |
| May 16, 2018 Filed May 18, 2018 14:19 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 214,000 | $1.91 Strike: $1.91 | $408,740.00 |
DisclosureSEC source: 0001209191-18-031290 · doc4.xml · derivative · entry 1 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,000 Underlying: Stock Options · 214,000 shares Expires 2028-05-16 F1 · kind: 25% vesting on the anniversary of the vesting determination date and 1/48th per month thereafter; being fully vested on the fourth anniversary of the vesting determination date. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 02:36 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock,$.01 par value | 39,840 | $2.52 | $100,396.80 |
DisclosureSEC source: 0001209191-17-066902 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,840 Read SEC document |
| February 16, 2017 Filed Mar 20, 2017 12:43 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.54 Strike: $0.54 | $216,000.00 |
DisclosureSEC source: 0001209191-17-021589 · doc4.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Stock Options · 400,000 shares Expires 2026-12-23 F2 · kind: 25% vesting on the anniversary of the vesting determination date and 1/48th per month thereafter; being fully vested on the fourth anniversary of the vesting determination date. Read SEC document |
| February 16, 2017 Filed Mar 20, 2017 12:43 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, Par $0.01 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-021589 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Corp VP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year anniversary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:42 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 17,422 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-16-051297 · form4.xml · derivative · entry 3 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,422 Underlying: Common Stock · 17,422 shares Expires 2026-05-03 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:42 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-051297 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,671 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019; and 2,046 RSUs which vest in two equal installments of 675 on 5/3/2018 and 5/3/2019 and one installment of 696 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2016 Filed Apr 29, 2016 00:50 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 254 | $162.85 | $41,363.90 |
DisclosureSEC source: 0001127602-16-050231 · form4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,625 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 26, 2016 Filed Apr 29, 2016 00:50 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 181 | $163.46 | $29,586.26 |
DisclosureSEC source: 0001127602-16-050231 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,879 Read SEC document |
| March 25, 2016 Filed Mar 29, 2016 21:35 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,703 | $149.24 | $403,395.72 |
DisclosureSEC source: 0001127602-16-047742 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,060 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 449 RSUs which vest on 4/27/2016; 658 RSUs which vest in one installment of 324 on 4/26/2016 and one installment of 334 on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 279 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 02, 2016 Filed Mar 4, 2016 23:26 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-045134 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,678 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 449 RSUs which vest on 4/27/2016; 658 RSUs which vest in one installment of 324 on 4/26/2016 and one installment of 334 on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 237 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2016 Filed Feb 2, 2016 01:41 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 251 | $152.73 | $38,335.23 |
DisclosureSEC source: 0001127602-16-038857 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,478 F1 · balance_after: These shares include 237 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 449 RSUs which vest on 4/27/2016; 658 RSUs which vest in one installment of 324 on 4/26/2016 and one installment of 334 on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| October 25, 2015 Filed Oct 27, 2015 22:16 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 569 | $155.75 | $88,621.75 |
DisclosureSEC source: 0001127602-15-029630 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,696 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 449 RSUs which vest on 4/27/2016; 658 RSUs which vest in one installment of 324 on 4/26/2016 and one installment of 334 on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 00:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 242 | $167.91 | $40,634.22 |
DisclosureSEC source: 0001127602-15-015489 · form4.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,187 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 449 RSUs which vest on 4/27/2016; 658 RSUs which vest in one installment of 324 on 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 186 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 26, 2015 Filed Apr 29, 2015 00:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 176 | $167.91 | $29,552.16 |
DisclosureSEC source: 0001127602-15-015489 · form4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,429 Read SEC document |
| April 25, 2015 Filed Apr 29, 2015 00:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 318 | $167.91 | $53,395.38 |
DisclosureSEC source: 0001127602-15-015489 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,605 Read SEC document |
| April 23, 2015 Filed Apr 24, 2015 20:53 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 3,012 | $169.31 | $509,963.83 |
DisclosureSEC source: 0001127602-15-015086 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,923 F1 · price: The price reported is an average price. The prices ranged from $169.355 to $169.22 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 27, 2015 Filed Mar 31, 2015 23:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 3,711 | $160.55 | $595,801.05 |
DisclosureSEC source: 0001127602-15-012987 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,935 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 02:14 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 8,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010550 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,561 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 179 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.